Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by * % change in forced vital capacity (FVC) * % fibrosis in high resolution computed tomography (HRCT) of the lung
Epistemonikos ID: baa64d1fca7bcab3b3420a38c8847a086001307d
First added on: Oct 30, 2020